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Abstract
Background: In 2006, Brazil began routine immunization of infants ,15 wk of age with a single-strain rotavirus vaccine. We
evaluated whether the rotavirus vaccination program was associated with declines in childhood diarrhea deaths and
hospital admissions by monitoring disease trends before and after vaccine introduction in all five regions of Brazil with
varying disease burden and distinct socioeconomic and health indicators.
Methods and Findings: National data were analyzed with an interrupted time-series analysis that used diarrhea-related
mortality or hospitalization rates as the main outcomes. Monthly mortality and admission rates estimated for the years after
rotavirus vaccination (2007–2009) were compared with expected rates calculated from pre-vaccine years (2002–2005),
adjusting for secular and seasonal trends. During the three years following rotavirus vaccination in Brazil, rates for diarrhea-
related mortality and admissions among children ,5 y of age were 22% (95% confidence interval 6%–44%) and 17% (95%
confidence interval 5%–27%) lower than expected, respectively. A cumulative total of ,1,500 fewer diarrhea deaths and
130,000 fewer admissions were observed among children ,5 y during the three years after rotavirus vaccination. The
largest reductions in deaths (22%–28%) and admissions (21%–25%) were among children younger than 2 y, who had the
highest rates of vaccination. In contrast, lower reductions in deaths (4%) and admissions (7%) were noted among children
two years of age and older, who were not age-eligible for vaccination during the study period.
Conclusions: After the introduction of rotavirus vaccination for infants, significant declines for three full years were
observed in under-5-y diarrhea-related mortality and hospital admissions for diarrhea in Brazil. The largest reductions in
diarrhea-related mortality and hospital admissions for diarrhea were among children younger than 2 y, who were eligible
for vaccination as infants, which suggests that the reduced diarrhea burden in this age group was associated with
introduction of the rotavirus vaccine. These real-world data are consistent with evidence obtained from clinical trials and
strengthen the evidence base for the introduction of rotavirus vaccination as an effective measure for controlling severe and
fatal childhood diarrhea.
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In July 2009, the World Health Organization recommended
introduction of rotavirus vaccines into national immunization
programs of all countries worldwide for controlling severe
rotavirus disease, which accounts for approximately one-third of
the 1.34 million diarrhea deaths and 9 million hospital admissions
worldwide among children younger than 5 y of age [1–3].
Evaluating the health impact of large-scale programs, and
ensuring their equity, is considered a top priority in global health
for well-informed policy decisions [4–6]. This is particularly
important for rotavirus vaccine programs because challenges
remain concerning performance of the vaccine in regions with the
highest morbidity and mortality [7,8].
The protective effect of rotavirus vaccines has been assessed in
various high-, middle-, and low-income settings. For unclear
reasons, efficacy of live, oral rotavirus vaccines is location-
dependent, with a gradient in immune response and protective
efficacy that correlates with the socioeconomic status of the
population [7,8]. In a clinical trial from Latin America, the single-
strain human rotavirus vaccine Rotarix (GlaxoSmithKline Bio-
logicals) showed a protective efficacy of 85% against severe
rotavirus disease (i.e., hospital admissions) [9,10]. Efficacy was
lower in the middle-income settings of South Africa (77%) and El
Salvador (76%) and the low-income setting of Malawi (49%)
[11,12]. A similar gradient in efficacy has also been shown for the
pentavalent rotavirus vaccine RotaTeq (Merck) in clinical trials
[13–15] and post-licensure evaluations [16–18].
Although rotavirus vaccines have only recently been intro-
duced, the population-level effect of vaccination has been assessed
in various settings. A large reduction in national diarrhea hospital
admissions after the introduction of pentavalent rotavirus vaccine
has been shown in high-income settings [19–22]. While these
data are promising, evaluations from middle- and low-income
settings, most of which are using the single-strain vaccine [23],
are limited. A recent study from Mexico demonstrated significant
reductions in infant diarrhea mortality early after rotavirus
vaccine introduction [24]. Early evaluations of the impact of
rotavirus vaccine in Brazil have shown a reduction in rotavirus
and diarrhea hospitalizations during the first year after vaccine
introduction [25–27]. However, Brazil is a large country with
heterogeneous socioeconomic conditions and a high burden of
diarrheal disease, where diarrhea deaths and admissions occur
year-round and disease trends had been declining in recent years
before vaccination [28]. In such settings, accounting for secular
declines and monitoring diarrhea trends for a longer duration
after vaccine introduction are necessary to isolate the effect of
vaccine from other concurrently implemented interventions or
changes in practice. Thus, we conducted a comprehensive
national evaluation quantifying the sustained effect of a
vaccination program in Brazil on both relevant outcomes,
diarrhea deaths and diarrhea admissions from all causes, using
an interrupted time-series analysis.
In 2006, the Brazilian Ministry of Health introduced the single-
strain rotavirus vaccine, Rotarix, simultaneously in all 27 states
through its national immunization program in order to accelerate
reaching the fourth Millennium Development Goal of reduced
child mortality. The primary objective of this study was to evaluate
the effect of rotavirus vaccination by analyzing trends in mortality
and hospital admissions for diarrhea due to all causes among
young children in the five regions of Brazil.
Methods
Ethics Statement
This evaluation involved analysis of existing, publicly available
datasets. Because these are publicly available non-identifiable data,
the Brazilian Ministry of Health and the United States Centers for
Disease Control and Prevention human subjects’ offices deemed
that an ethics statement was not required for this work.
Setting and Design
Brazil is a middle-income Latin American country with an
annual birth cohort of ,3 million infants and a gross domestic
product per capita of US$8,300. Brazil’s 27 states are divided into
five geographic regions (North, Northeast, Southeast, South, and
Central-West) with distinct socioeconomic and health indicators
(Table 1). The United Nations Development Program classifies
countries with a human development index (HDI) below 0.90 as
‘‘developing’’ [29]. In 2005, among 182 countries ranked in
decreasing order of HDI, Brazil overall (HDI =0.805) ranked 75
th
(for general comparison, Mexico [HDI =0.844] ranked 53
rd and
the United Kingdom ranked 21
st [HDI =0.947]). The Northeast
region of Brazil individually had an index (HDI =0.720) below that
of Bolivia (HDI =0.722), a developing country that ranked 113
th.
Table 1. Basic demographic, socioeconomic, and health indicators in Brazil, by region.
Region HDI
a
Population ,1y ,
2009
b
,5-y Mortality per 1,000
Live Births, 2005
c
Percent Deaths ,5 y Due
to Diarrhea, 2005
c
Rotavirus Vaccine Coverage
among Children ,1y
d
2008 2009
All regions 0.805 3,013,689 25.4 4.1 81.3 84.3
Northeast 0.72 1,005,387 37.3 6.5 79.0 82.4
North 0.764 309,789 27.6 6.2 64.6 69.5
Central-West 0.815 232,233 21.2 3.5 85.1 89.4
Southeast 0.824 1,119,725 17.9 1.7 86.1 87.9
South 0.829 346,555 16.1 1.7 84.6 87.3
aThe HDI is a summary index that ranges from 0 (lowest) to 1 (highest), composed of life expectancy at birth, adult literacy rate, school enrollment rate, and per capita
gross domestic product. The index is produced by the United Nations Development Program. HDIs for Brazilian regions were last published in 2005 [29].
bSource: Ministry of Health, Brasilia, Brazil [33].
cHealth Indicator and Basic Data in Brazil (IDB) [32]. The ,5-y mortality per 1,000 live births denotes the probability of dying between age 0 and 5 y per 1,000 live births.
dVaccination coverage estimated based on number of second doses of rotavirus vaccine administered divided by the estimated population ,1 y of age. Source:
National Immunization Program, Ministry of Health, Brasilia, Brazil [31].
doi:10.1371/journal.pmed.1001024.t001
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Brazil’s national immunization program operates within the
Sistema Unico de Sau ´de (SUS), Brazil’s publicly funded health-
care system, to provide universal access to recommended vaccines
[30]. The federal government purchases vaccines, which are
distributed to state and local immunization programs and
provided at no cost at public health facilities throughout the
country. In April 2006, a rotavirus vaccine (Rotarix) was
introduced into Brazil’s national immunization program. Vacci-
nation is recommended at 2 and 4 mo of age. The first dose can be
administered at 6–14 wk, and the second dose at 14–24 wk of age.
Rotavirus vaccination coverage estimates for 2007 through 2009
among children under 1 y of age were obtained for each region
from the information department of the Ministry of Health [31].
Doses of rotavirus vaccine administered during the years 2007
through2009,registeredasafirstorseconddose,wererecordedina
national electronic database by clinics providing immunization
services. Coverage with two doses of oral rotavirus vaccine was
estimated as the number of second doses administered divided by
the population ,1 y of age in the corresponding calendar year.
Diarrhea Admissions and Death Data
Data on diarrhea deaths were obtained from the Mortality
Information System (Sistema de Informac ¸o ˜es sobre Mortalidade
[SIM]) of the Brazilian Ministry of Health, the national database of
information collected from death certificates [32]. This system is
estimated to capture 90% of all deaths that occur in Brazil, with lower
percentages (,80%) in the North and Northeast regions. Capture of
neonatal deaths is lower, but neonatal deaths account for a small
proportion (,3%–4%) of diarrhea deaths in Latin America [1]. Data
on admissions were obtained from the electronic Hospital Information
System (Sistema de Informac ¸o ˜e sH o s p i t a l a r e s[ S I H ] )o fS U S[ 3 2 ] .T h i s
system includes information on all hospital admissions authorized for
payment by SUS, which covers approximately 70% of hospitalizations
in Brazil. The hospitalization data are from public hospitals and some
private hospitals that are paid by the government to care for patients.
Nochanges occurred during thestudyperiod in termsof thenumber of
hospitals that reported to this system. Both the SIM and SIH use the
International Classification of Diseases (ICD-10) for causes of death
(SIM) or admission diagnosis (SIH). In this analysis, we included deaths
and admissions with the principal cause coded as diarrheal disease of
any cause (ICD-10 codes: A00–A03, A04, A05, A06.0–A06.3, A06.9,
A07.0–A07.2, A07.9, A08–A09) among children younger than 5 y
from January 2002 through December 2009.
Statistical Analysis
Rates of all-cause diarrhea-related deaths and admissions
among children younger than 5 y of age were examined before
Figure 1. Trends in childhood diarrhea deaths and admissions in Brazil. Each analysis examines trends from 2002–2009, by age, including
comparison of observed events (blue dots) after rotavirus vaccination (2007 to 2009) in Brazil with expected events (solid line) and 95% CIs (gray
shaded area) in the absence of vaccination. Expected number of events and 95% CIs are based on predictions from regression models fitted to
historic data from each region (2002 to 2005).
doi:10.1371/journal.pmed.1001024.g001
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rotavirus vaccination using an interrupted time-series analysis. We
excluded data from 2006, the year in which the vaccine was
introduced. These rates were calculated from SIM and SIH figures
for diarrhea-related events per month and population, using
annual projections from the 2000 census [33].
For the regression analysis, a generalized linear model was fit
to the time-series data, assuming that the diarrhea deaths and
admissions were Poisson distributed. The standard error of the
rate ratio was scaled to the Pearson chi-squared statistic divided
by the residual degrees of freedom to account for over-dispersion
of the monthly counts in the outcome data for all models [34].
We first computed monthly rates of diarrhea-related deaths and
admissions ‘‘expected’’ to occur in the absence of a rotavirus
vaccination program by fitting the model to pre-vaccine data
(2002 through 2005). We adjusted for seasonality by including an
indicator variable for each calendar month and for secular trends
by including calendar year in the model. The sequential year
term captured the linear slope of decreasing secular trend; we
assumed that this linear trend continued into the vaccine era
(2007 through 2009). This model based on pre-vaccine data
(including a constant and terms for month and year) was used to
estimate expected values in the vaccine era. We then compared
the absolute number of diarrhea-related deaths and admissions
observed in the vaccine era with those expected in the absence of
vaccination, as computed by the model, to assess the potential
impact of vaccination. Finally, we calculated the rate ratio of
diarrhea deaths and admissions in the vaccine era with the
inclusion of an indicator variable for the period after rotavirus
vaccine introduction; again, we controlled for seasonal and
secular trends.
We investigated changes in rates of diarrhea deaths and
admissions by age groups (under 1 y, 1 to ,2 y, 2 to 4 y) because
vaccine coverage during the early years of an immunization
program and disease rates vary substantially by age. Separate
models were also fitted for each region of Brazil in order to
investigate differential impact of the vaccine program and to allow
for different seasonality of rotavirus and secular trends. Results are
presented as percent decline (1 2 rate ratio) and 95% confidence
interval (CI). Analyses were done with Stata (version 11).
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Figure 2. Impact of rotavirus vaccination on monthly events of childhood diarrhea deaths in Brazil by region. Each analysis compares
the monthly observed events among children under 5 y after rotavirus vaccination (2007 to 2009) with expected events in the absence of
vaccination, by region. Expected number of events and 95% CIs are based on predictions from regression models fitted to historic data from each
region (2002 to 2005).
doi:10.1371/journal.pmed.1001024.g002
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Vaccination Coverage
In 2007, when an estimated 80% of children younger than 1 y of
age received two doses of rotavirus vaccine, only 47% of those 1 to
,2 y of age, and none of those 2 to 4 y of age had been completely
immunized. By 2009, an estimated 84% of children younger than
1 y of age (Table 1) 81% of children 1 to ,2 y of age, and 36% of
children 2 to 4 y of age had received two doses of rotavirus vaccine.
Diarrhea-Related Deaths
From 2002 through 2005, an annual median of 2,700 diarrhea-
related deaths occurred among children younger than 5 y at an
average annual rate of 16 deaths per 100,000, accounting for 14%
of the 19,000 post-neonatal deaths (i.e., 30 d to 5 y of age) in Brazil
each year. Prior to rotavirus vaccine introduction, there was a
trend of declining diarrhea-related mortality among children
younger than 1 y (relative reduction [RR] =0.87/y; 95% CI
0.83–0.94; p,0.001), 1 to ,2 y of age (RR =0.96/y; 95% CI
0.91–1.02; p=0.23) and 2 to 4 y of age (RR=0.93/y; 95% CI
0.87–1.00; p=0.06) (Figure 1). Diarrhea mortality rates and
seasonality differed significantly by region (Figure 2). A majority
(73%) of diarrhea-related deaths occurred in the North and
Northeast, where mortality rates were four to five times higher
than those in the Central-West, South, and Southeast.
Compared to expected rates based on pre-vaccine trends,
diarrhea-associated mortality among children younger than 5 y of
age was 22% (95% CI 6%–44%) lower during the three years after
rotavirus vaccination (2007 through 2009; Table 2). Additionally,
in the month-to-month comparison of observed versus expected
Table 2. Post-vaccination changes in numbers of diarrhea-related deaths and mortality rates among children younger than 5 y by
December 2009 in Brazil.
Region and Age Group
Annual Number of Diarrhea Deaths Post-
Vaccination (2007–2009)
Annual Death Rate (per 100,000) Post-
Vaccination (2007–2009)
Percent Decline in
Death Rates (95% CI)c
Observed
a Expected
b Observed
a Expected
b
All regions
,1 y 1,086 1,240 35 48 22 (6 to 35)
1 y 232 280 7 11 28 (6 to 45)
2–4 y 116 100 1 1 4 (30 to 29)
Total 1,435 1,610 9 12 22 (6 to 44)
North
,1 y 194 276 61 88 25 (1 to 44)
1 y 57 180 18 56 61 (36 to 76)
2–4 y 22 48 2 4 61 (25 to 80)
Total 272 468 17 29 38 (21 to 51)
Northeast
,1 y 624 864 61 86 20 (25t o4 0 )
1 y 105 132 10 13 11 (229 to 38)
2–4 y 59 60 2 2 234 (299 to 10)
Total 788 1,056 15 21 17 (28t o3 6 )
Southeast
,1 y 158 204 14 18 24 (4 to 41)
1 y 28 24 2 2 0 (267 to 41)
2–4 y 17 12 0 0 212 (2172 to 53)
Total 204 252 3 4 19 (21t o3 5 )
South
,1 y 42 60 12 17 33 (1 to 55)
1 y 12 12 3 2 11 (2133 to 66)
2 – 4 y 60 10 263 (2694 to 62)
Total 61 72 3 4 26 (28t o5 0 )
Central-West
,1 y 68 72 29 32 11 (238 to 43)
1 y 30 48 13 19 47 (29t o7 4 )
2–4 y 11 12 2 1 37 (285 to 72)
Total 110 132 9 11 22 (215 to 48)
aObserved number of deaths are annual means for 2007–2009; observed rates are estimated annual rates for 2007–2009 from the regression model.
bExpected in the absence of vaccination on the basis of 2002–2005 data, adjusting for seasonality and secular trends.
cCalculated as 1 2 RR of diarrhea deaths post-vaccine compared to the pre-vaccine era from Poisson regression models, adjusting for seasonality and secular trends.
doi:10.1371/journal.pmed.1001024.t002
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post-vaccination period (Figure 2), with most prominent reduc-
tions during January through March. Similar declines in diarrhea
deaths among children younger than 5 y of age were observed
during each post-vaccination year, with a 21% reduction (95% CI
6%–34%) in 2007, a 24% reduction (95% CI 7%–38%) in 2008,
and a 33% reduction (95% CI 14%–47%) in 2009.
Among all children younger than 5 y of age, observed mortality
rates post-vaccination declined significantly in all regions, with
largest absolute reductions occurring in high mortality regions of
North and Northeast Brazil (Table 2). Among children younger
than 1 y of age, observed rates were significantly lower than
expected in all regions. Among 1- to ,2-y-old children, the
absolute declines in diarrhea-associated mortality in the North
accounted for most of the overall declines in this age group.
During each post-vaccination year, diarrhea-related mortality
among children younger than 5 y of age was lower than expected
in all but one region of Brazil (Figure 3). While a decline in
mortality was not observed in the Central-West region (22%;
95% CI 274% to 41%) in 2009 (Figure 3), overall diarrhea
mortality during 2007–2009 for this region was non-significantly
lower (22% decline; 95% CI 215% to 48%) than expected.
In total, during 2007–2009, approximately 1,500 fewer diarrhea-
related deaths were observed in Brazil compared to that expected
without a vaccine program among children under 5 y of age.
Diarrhea-Related Admissions
During the pre-vaccine period, there were a total of ,1,091,000
hospital admissions for diarrhea from all causes reported through
the SUS among children younger than 5 y, giving an average
annual rate of 1,593 per 100,000. Similar to diarrhea-related
deaths, significant declining trends prior to vaccine introduction
were also observed in diarrhea-related admissions among children
younger than 1 y of age (RR=0.93/y; 95% CI 0.90–0.97;
p,0.001), but not in children 1 to ,2 y of age (RR=0.99/y; 95%
CI 0.94–1.04; p=0.66) or 2 to 4 y of age (RR=0.98/y; 95% CI
0.94–1.03; p=0.59) (Figure 1). Unlike diarrhea-related deaths,
which were mostly concentrated in the poorest North and
Northeast regions, diarrhea-related hospital admissions occurred
throughout Brazil. However, the highest expected diarrhea
admission rates (per 100,000) were in the less developed North
(2,915) and Northeast (2,070) and the lowest rates in the more
developed Southeast (666) and South (892) regions of Brazil
(Table 3).
Figure 3. Change in diarrhea mortality and admission rates after vaccination by year and region. The maps depict the percent change in
observed rates of diarrhea mortality and admission after rotavirus vaccination in Brazil compared to expected rates without a vaccination program, by
year and region. Expected numbers of events are based on predictions from regression models fitted to historic data from each region (2002 to 2005).
The percent declines are computed as one minus the RR of diarrhea events post-vaccine compared to the pre-vaccine era from Poisson regression
models, adjusting for seasonality and secular trends.
doi:10.1371/journal.pmed.1001024.g003
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observed annual hospital admission rates for diarrhea among
children younger than 1 y and children 1 to ,2 y of age were 637
and 601 per 100,000 lower than the expected rates without
vaccination (Table 3), reductions of 25% (95% CI 14%–34%) and
21% (95% CI 7%–33%; p,0.001), respectively. Reduction in
diarrhea-related hospital admissions was most prominent during
May to October (Figure 4). Countrywide observed diarrhea-
related hospital admissions among children younger than 5 y of
age were lower than expected during each post-vaccination year,
with a 21% reduction (95% CI 9%–31%) in 2007, an 11%
reduction (95% CI 25% to 24%) in 2008, and a 24% reduction
(95% CI 8%–37%) in 2009. Compared to expected rates,
significantly lower diarrhea-related hospital admission rates were
observed in four out of five regions (Table 3). In the South,
diarrhea-related hospital admissions were 12% (95% CI 28% to
29%) lower than expected in 2007 and 11% (95% CI 219% to
33%) lower than expected in 2009, but above the expected by
27% (95% CI 0%–62%) during 2008 (Figure 3).
Overall, during 2007–2009, a 17% (95% CI 5%–27%)
reduction, or approximately 130,000 fewer diarrhea-related
hospital admissions (,42,480 per year), was observed compared
to the number of admissions expected in the absence of
vaccination among children under 5 y of age in Brazil.
Discussion
The introduction of a single-strain rotavirus vaccine in the
childhood immunization program in Brazil was associated with a
significant nationwide decline in diarrhea-related deaths and
hospital admissions among children younger than 5 y of age.
Reductions in mortality are consistent with results from Mexico,
Table 3. Changes in number and rates of hospital admissions for diarrhea due to all causes among children ,5 y by December,
2009, Brazil.
Region and Age Group
Annual Number of Diarrhea
Admissions Post-Vaccination
Annual Diarrhea Admission Rate
(per 100,000) Post-Vaccination
Percent Decline in Admission
Rates (95% CI)c
Observed
a Expected
b Observed
a Expected
b
All regions
,1 y 59,452 76,788 1,840 2,477 25 (14 to 34)
1 y 71,088 78,384 1,886 2,487 21 (7 to 33)
2–4 y 56,933 76,200 722 774 7 (27 to 19)
Total 187,472 229,956 1,165 1,429 17 (5 to 27)
North
,1 y 11,682 16,212 3,679 5,107 23 (10 to 34)
1 y 13,375 17,856 4,168 5,565 17 (1 to 30)
2–4 y 12,539 13,812 1,258 1,386 7 (27 to 19)
Total 37,595 47,664 2,300 2,915 16 (3 to 27)
Northeast
,1 y 26,240 36,324 2,584 3,578 27 (14 to 38)
1 y 27,097 36,708 2,661 3,605 23 (9 to 34)
2–4 y 32,987 34,344 1,064 1,108 6 (29 to 19)
Total 86,325 106,284 1,681 2,070 19 (5 to 30)
Southeast
,1 y 9,929 14,160 852 1,216 29 (14 to 42)
1 y 9,383 12,960 782 1,079 26 (5 to 42)
2–4 y 12,571 14,016 331 369 8 (211 to 24)
Total 31,883 41,184 517 666 21 (3 to 36)
South
,1 y 4,931 5,040 1,366 1,398 9 (211 to 25)
1 y 5,140 5,148 1,374 1,378 2 (227 to 24)
2–4 y 7,586 7,320 623 601 26( 237 to 217)
Total 17,657 17,412 904 892 0 (224 to 20)
Central-West
,1 y 4,151 5,784 1,759 2,451 24 (1 to 42)
1 y 4,456 6,984 1,871 2,938 30 (3 to 49)
2–4 y 5,404 7,764 743 1,069 31 (5 to 44)
Total 14,012 20,412 1,166 1,699 26 (4 to 44)
aObserved number of hospital admissions are annual means for 2007–2009; observed rates are estimated annual rates for 2007–2009 from the regression model.
bExpected in the absence of vaccination on the basis of 2002–2005 data, adjusting for seasonality and secular trends.
cCalculated as 1 2 RR of diarrhea deaths post-vaccine compared to the pre-vaccine era from Poisson regression models, adjusting for seasonality and secular trends.
doi:10.1371/journal.pmed.1001024.t003
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same year (2006) [24]. However, Brazil is one of several countries
in which substantial reductions in hospital admissions due to
diarrhea have been shown following introduction of rotavirus
vaccination into the national immunization program [19,20].
Prevention of rotavirus-related admissions is particularly impor-
tant for middle- and high-income countries in which nonfatal
rotavirus diarrhea is a common cause of childhood morbidity. The
results from Brazil suggest protection of rotavirus vaccination
against both diarrhea deaths and diarrhea-related hospital
admissions, adding to the strength of evidence supporting
investment in rotavirus vaccination to curtail the 1.3 million
deaths and 9 million hospital admissions related to diarrhea that
occur annually worldwide.
In Brazil, we observed a reduction of approximately 40,000
admissions per year (i.e., nearly one in five diarrhea-related
hospital admissions averted) among children under 5 y of age
during 2007–2009. Declines in diarrhea-related hospital admis-
sions were substantial both in the more developed South and
Southeast regions, as well as in the poorest regions of Brazil (North
and Northeast), where socioeconomic and health indicators
approximate those of less developed countries. Because the
baseline burden of diarrhea is three to five times greater in the
North and Northeast than in other regions of Brazil, the absolute
reduction in diarrhea-related deaths and diarrhea-related hospital
admissions was much greater in this population. Lower rotavirus
vaccine efficacy and immunogenicity have been observed in
impoverished populations of Latin America, Asia, and Africa that
have the highest risk of severe disease [11,13,18]. Significant
reductions in diarrhea-associated mortality in the North of Brazil
suggest that children living in areas with limited access to health
care who are at highest risk of dying from diarrheal illnesses
benefitted from vaccination.
Several pertinent findings support rotavirus vaccination as the
most likely explanation for the reduction in diarrhea-related
deaths and admissions. First, our estimates of decline were
adjusted for seasonal fluctuations and secular declines in trends
of diarrhea deaths and admissions. Second, the decline among
vaccinated age groups was sustained on a national level for three
full years after vaccine introduction. Third, the reduction in
10000
15000
20000
25000
30000
2 00 7m 1 2 00 8m 1 2 00 9m 1 2 01 0m 1
Brazil
1000
2000
3000
4000
5000
6000
2 00 7m 1 2 00 8m 1 2 00 9m 1 2 01 0m 1
North
4000
6000
8000
10000
12000
14000
2 00 7m 1 2 00 8m 1 2 00 9m 1 2 01 0m 1
NorthEast
2000
3000
4000
5000
6000
7000
2 00 7m 1 2 00 8m 1 2 00 9m 1 2 01 0m 1
SouthEast
500
1000
1500
2000
2500
2007 2008 2009 2010
South
1000
2000
3000
4000
2007 2008 2009 2010
CentralWest
N
u
m
b
e
r
 
o
f
 
D
i
a
r
r
h
e
a
 
A
d
m
i
s
s
i
o
n
s
Year
•￿￿￿ Observed admissions
Expected admissions
95% Confidence interval
￿￿￿￿ Observed admissions
Expected admissions
95% Confidence interval
Figure 4. Impact of rotavirus vaccination on monthly events of diarrhea admissions in Brazil by region. Each analysis compares the
monthly observed events among children under 5 y after rotavirus vaccination (2007 to 2009) with expected events in the absence of vaccination, by
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1 y or less, who had high rates of vaccination, than in those 2 to
4 y of age, who were not eligible for rotavirus immunization
during the study period.
Lastly,seasonalbluntinginmortalityandadmissionswasnotedin
several regions. Seasonality in rotavirus disease in Brazil varies by
region and study [35–37]. In the South, Central-West, and
Southeast regions of Brazil, previous surveillance indicated that
seasonal peaks in rotavirus admissions occur during May to
October, although year-round detection of the virus has also been
reported [35,36]. Our observation of the largest declines in diarrhea
admissions during these months of peak rotavirus activity supports
the contention that vaccination might have had a causal role. Data
aresparse on the seasonality of rotavirusin the North and Northeast
regions of Brazil, although one study suggests year-round detection
of rotavirus [37], which is consistent with our finding of year-round
decreases in diarrhea mortality in these regions.
We were intrigued by the increase in diarrhea-related hospital
admissions during 2008 in the South despite high vaccination
coverage, which contributed to an overall lower decline in diarrhea-
relatedhospitaladmissions nationally during the same year. In 2007
and 2008, G2P[4] was the predominant rotavirus strain circulating
in Brazil, a strain fully heterotypic to the G1P[8] vaccine used in
Brazil, prompting a debate about whether vaccine pressure
contributed to its emergence [38–40]. While emergence of this
strain might explain the higher diarrhea-related hospital admission
rates in the South during 2008, we think this is unlikely because the
single-strain rotavirus vaccine provided good heterotypic cross-
protection against G2P[4] strains in Brazil [26], and a similar
G2P[4] strain predominated in the South as well as in other regions
that had sustained declines in diarrhea-related disease. The
possibility also exists that an accumulation of older susceptible
children in 2008 who were unexposed to rotavirus during 2007
because of the large declines in rotavirus disease during that year
might have contributed to an increase in the intensity of
transmission during 2008 [41]. However, we suspect this is also
unlikely to fully explain the increase in the South because similar
increases should have been observed across Brazil. One possible
explanation for greater than expected diarrhea-related hospital
admissions in 2008 in the South of Brazil is circulation of other
enteric pathogens causing a regional epidemic of diarrhea.
Several factors could affect the interpretation of our findings,
primarily relating to the ecological nature of our study. Ecological
studies can be informative but have several shortcomings. Because
these studies do not link an exposure to an outcome at an individual
level, they may be prone to ecological fallacy (i.e., those unexposed
get the disease). Confounding biases such as seasonal periodicity of
disease, secular declines in trends, contribution of simultaneously
implemented interventions, and changes in coding and health-care
treatment patterns cannot be directly assessed with these studies
becauseoftheabsence ofacontrolgroup[42].Althoughweadjusted
for seasonality and secular declines in diarrhea mortality and
admissions, we cannot be fully confident that changes in coding or
treatment practices did not occur during the study period. While we
do not have evidence suggesting that reporting of diarrhea deaths
changedoverthestudyperiod,adecreaseinreporting ofdeathsafter
rotavirus vaccine introduction could be misinterpreted as vaccine
effectiveness. However, any changes in reporting would likely have
affected all age groups, and led to decline of mortality or admissions
in both older and younger children. The persistent reductions in
diarrhea deaths and diarrhea-related hospital admissions across all
regions, and the gradient in observed declines, with the lowest
reduction in the oldest children, who were not immunized with the
rotavirus vaccine, are consistent with vaccine-associated effects.
Programmaticrealitiesaresuchthat diagnostictesting is typicallynot
done for etiologic confirmation of diarrhea. Thus, we used all-cause
diarrhea codes to assess vaccine impact. Although this may provide
less precision with regard to vaccine effect on rotavirus disease, we
suspect thatmeasuring impacton all-cause diarrhea ismorevaluable
to decision makers and the public health community because it
provides an estimate of the preventable fraction of diarrhea deaths
and admissions attributable to rotavirus.
In summary, this time-series analysis provides evidence of
substantial reductions following the introduction of rotavirus
vaccination of both diarrhea-related deaths and diarrhea-related
hospital admissions from a large middle-income country in the
Americas with both developing and developed regions. These
findings have important global health policy implications. In low-
income countries, the main impetus for introduction of rotavirus
vaccines has been the potential to prevent rotavirus deaths: the
consistency in findings of a sustained reduction in diarrhea
mortality after rotavirus vaccination in Mexico [24] and Brazil
suggests that rotavirus vaccination is an important tool for
reducing the global burden of diarrhea deaths. In middle-income
countries that are not eligible for financial support from donors,
the potential reductions in diarrhea-related hospital admissions
and other health-care costs will be important for cost-effectiveness
considerations to justify the purchase of these relatively expensive
vaccines. The reductions in diarrhea-related hospital admissions
observed in Brazil, especially in low-mortality and higher income
regions, are also relevant for decisions in higher income countries
that have not yet introduced rotavirus vaccines into their routine
immunization programs.
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Background. Diarrheal disease, usually caused by infectious
agents, is the second major cause of death in children aged
under five years. As highlighted in a recent PLoS Medicine
series, access to clean water and improved sanitation is the
key to the primary prevention of diarrheal illnesses. Yet
despite the targets of Millennium Development Goal 7 to
half the number of people without access to clean water or
improved sanitation by 2015, over one billion people
worldwide do not currently have access to clean water and
over two billion do not currently have access to improved
sanitation.
Since enteric viruses are primarily transmitted directly from
one person to another, they cannot be controlled completely
by improvements in sanitation. Therefore, although not
replacing the urgent need to provide access to clean water
and improved sanitation for all, vaccination programs that
protect young children against some infections that cause
diarrhea, such as rotavirus, which accounts for one-third of
all child deaths caused by diarrhea, are a pragmatic way
forward. As large clinical trials have shown the safety and
efficacy of rotavirus vaccines in population settings, in July
2009, the World Health Organization recommended includ-
ing rotavirus vaccines into every country’s national immuni-
zation programs.
Why Was This Study Done? Although the protective
effect of rotavirus vaccines has been assessed in various
high-, middle-, and low-income settings, for reasons that
remain unclear, the efficacy of live, oral rotavirus vaccines
appears to be dependent on geographical location and
correlated to the socioeconomic status of the population.
Because of these concerns, evaluating the health impact of
large-scale rotavirus vaccine programs and ensuring their
equity in a real-world setting (rather than in clinical trial
conditions) is important.
Therefore, the researchers addressed this issue by conduct-
ing this study to evaluate the effect of rotavirus vaccination
on mortality and hospital admissions for diarrhea due to all
causes among young children in the five regions of Brazil.
The researchers chose to do this study in Brazil because of
the high incidence of diarrhea-related deaths and hospital
admissions and because five years ago, in July 2006, the
Brazilian Ministry of Health introduced the single-strain
rotavirus vaccine simultaneously in all 27 states through its
national immunization program—allowing for ‘‘before’’ and
‘‘after’’ intervention analysis.
What Did the Researchers Do and Find? The researchers
obtained data on diarrheal deaths and hospital admissions in
children aged under five years for the period 2002–2005 and
2007–2009 and data on rotavirus vaccination rates. The
researchers got the data on diarrhea deaths from the
Brazilian Mortality Information System—the national
database of information collected from death certificates
that covers 90% of all deaths in Brazil. The data on hospital
admissions came from the electronic Hospital Information
System of Brazil’s Unified Health System (Sistema Unico de
Sau ´de, SUS)—the publicly funded health-care system that
covers roughly 70% of the hospitalizations and includes
information on all admissions (from public hospitals and
some private hospitals) authorized for payment by the
Unified Health System. The researchers got regional rotavirus
vaccination coverage estimates for 2007–2009 from the
information department of the Ministry of Health, and
estimated coverage of the two doses of oral rotavirus
vaccine by taking the annual number of second doses
administered divided by the number of infants in the region.
In 2007, an estimated 80% of infants received two doses of
rotavirus vaccine, and by 2009, this proportion rose to 84%
of children younger than one year of age. The researchers
found that in the three years following the introduction of
rotavirus vaccination, diarrhea-related mortality rates and
admissions among children aged under five years were
respectively 22% and 17% lower than expected, with a
cumulative total of 1,500 fewer diarrhea deaths and 130,000
fewer admissions. Furthermore, the largest reductions in
deaths and admissions were among children who had the
highest rates of vaccination (less than two years of age), and
the lowest reductions were among children who were not
eligible for vaccination during the study period (aged 2–4
years).
What Do These Findings Mean? These findings suggest
that the introduction of rotavirus vaccination in all areas of
Brazil is associated with reduced diarrhea-related deaths and
hospital admissions in children aged under five years. These
real-world impact data are consistent with the clinical trials
and strengthen the evidence base for rotavirus vaccination
as an effective measure for controlling severe and fatal
childhood diarrhea.
These findings have important global policy implications. In
middle-income countries, such as Brazil, that are not eligible
for financial support from donors, the potential reductions in
admissions and other health-care costs will be important for
cost-effectiveness considerations to justify the purchase of
these still relatively expensive vaccines.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001024
N PLoS Medicine has published a series on water and
sanitation
N More information is available from the World Health
Organization on diarrheal illness in children
N More information is available about rotavirus vaccines from
the World Health Organization, the US Centers for Disease
Control and Prevention, and the Rotavirus Vaccine
Program
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